Clinical trial for Pneumonia
Official title Randomised Evaluation of COVID-19 Therapy
ClinicalTrials.gov ID: NCT04381936
What this study is testing
What is Lopinavir-Ritonavir?
This is an investigational medicine being studied to see if it helps treat pneumonia. It is designed to stop certain viruses from making new copies of themselves inside your body.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares different medicines to find out which, if any, reduce death in people with pneumonia, including COVID‑19 and other types.
- Who it's for
- Hospitalised adults and children with pneumonia, including those with COVID‑19.
- What's involved
- Participants may receive one of several treatments such as antiviral drugs, steroids, antibiotics, plasma, or other medicines, and will have regular check‑ups and tests to monitor their health.
- Time commitment
- The study lasts until the patient is discharged or the trial ends, with visits and tests scheduled as needed during hospital stay.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 0 and older
You may be able to join if
- typical symptoms of a new respiratory tract infection (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and...
- objective evidence of acute lung disease (e.g. consolidation or ground-glass shadowing on X-ray or CT, hypoxia, or compatible clinical examination)
- Confirmed influenza A or B infection (including patients with SARS-CoV-2 co-infection)
- Community-acquired pneumonia (CAP) with planned antibiotic treatment (excluding patients with suspected or confirmed SARS-CoV-2, influenza, active...
The study team makes the final eligibility decision.
Where it is enrolling
- Brussels, Belgium
- Tallinn, Estonia
- Paris, France
- Kumasi, Ghana
- Jakarta, Indonesia
- Roma, Italy
- Kathmandu, Nepal
- Utrecht, Netherlands
- Lisbon, Portugal
- Bucharest, Romania
- Johannesburg, South Africa
- Barcelona, Spain
- Stockholm, Sweden
- Oxford, United Kingdom
- Ho Chi Minh City, Vietnam
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Brussels, Belgium; Tallinn, Estonia; Paris, France; Kumasi, Ghana; Jakarta, Indonesia; Roma, Italy and 9 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.